LB-102 clinical trials
Also written LB-102.
How each study uses LB-102 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the LB-102 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LB-102
- 6
Studies by the year they started
6 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
LB Pharmaceuticals Inc. (6)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test LB-102, phase 3 first.
- Jun 2027Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute SchizophreniaPhase 3 · LB Pharmaceuticals Inc.
Studies
Open first, then newest update. How each study uses LB-102 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- 52-week Open Label Safety-Tolerability StudyRecruitingPhase 3LB Pharmaceuticals Inc.NCT07369154Written as LB-102
- Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.RecruitingPhase 2LB Pharmaceuticals Inc.NCT07494305Written as LB-102
- Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute SchizophreniaRecruitingPhase 3LB Pharmaceuticals Inc.NCT07363577Written as LB-102 (50 mg tablet)
- Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute SchizophreniaCompletedPhase 2LB Pharmaceuticals Inc.NCT06179108Written as LB-102
- Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy VolunteersCompletedPhase 1LB Pharmaceuticals Inc.NCT04588129Written as LB-102
- Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy AdultsCompletedPhase 1LB Pharmaceuticals Inc.NCT04187560Written as LB-102